Metolazone as Add‑On Therapy for Refractory Edema in Heart Failure

Indications & Guideline Recommendations

The American Heart Association recommends torsemide as a preferred loop diuretic in patients with impaired renal function due to its longer duration of action and superior oral bioavailability 3
The European Society of Cardiology suggests that torsemide's hepatic elimination pathway prevents drug accumulation in severe renal dysfunction, making it a better choice for patients with chronic kidney disease 4

Torsemide maintains stable pharmacokinetics regardless of renal function, with approximately 80% undergoing hepatic metabolism via CYP2C9, and only 20% requiring renal excretion 5
Bumetanide's elimination is significantly prolonged in renal impairment, with renal clearance markedly decreased, although total plasma clearance remains relatively preserved 5

The standard conversion ratio is: 40 mg furosemide = 1 mg bumetanide = 10-20 mg torsemide, as recommended by the American College of Cardiology 3
When switching from bumetanide to torsemide in renal impairment, multiply the bumetanide dose by 10-20 to determine the equivalent torsemide dose, according to the European Society of Cardiology 6
Torsemide: Start at 10-20 mg once daily, with a maximum dose of 200 mg daily, as suggested by the American Heart Association 3
Bumetanide: Start at 0.5-1.0 mg once or twice daily, with a maximum dose of 10 mg daily, according to the British Journal of Pharmacology 3

Assess clinical response within 1-2 days: Monitor daily weight, peripheral edema resolution, and jugular venous distention, as recommended by the American College of Cardiology 6
Check electrolytes within 3-7 days: Focus on potassium and magnesium, as both drugs cause dose-related potassium excretion, according to the European Society of Cardiology 3
Monitor renal function biomarkers: Greatest changes in serum creatinine occur after first doses, requiring close surveillance, as suggested by the British Journal of Pharmacology 4

If maximum torsemide doses (200 mg) fail, add sequential nephron blockade with metolazone 2.5-10 mg or hydrochlorothiazide 25-100 mg, as recommended by the American Heart Association 3
Consider IV conversion: Use at least twice the daily oral dose when switching to intravenous therapy for inadequate oral response, according to the European Society of Cardiology 7
Measure spot urine sodium 2 hours post-dose: Levels <50-70 mEq/L indicate insufficient natriuresis requiring intervention, as suggested by the American College of Cardiology 6